• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

NADA 140-833 Ivomec® Plus For Cattle - supplemental approval (March 21,1989)

Approval Date: March 21,1989

I. GENERAL INFORMATION:

NADA140-833
Sponsor:Merial Limited
2100 Ronson Road
Iselin, New Jersey 08830
Generic Name:ivermectin and clorsulon
Trade Name:Ivomec® Plus Injection for Cattle
Marketing Status: 

 

II. INDICATIONS FOR USE: For the treatment and control of the following in cattle.

Gastrointestinal roundwormsOstertagia ostertagiAdults and fourth-stage larvae
 Ostertagia ostertagiInhibited fourth-stage larvae
 Ostertagia lyrataAdults and fourth-stage larvae
 Haemonchus placeiAdults and fourth-stage larvae
 Trichostrongylus axeiAdults and fourth-stage larvae
 Trichostrongylus colubriformisAdults and fourth-stage larvae
 Cooperia oncophoraAdults and fourth-stage larvae
 Cooperia punctataAdults and fourth-stage larvae
 Cooperia pectinataAdults and fourth-stage larvae
 Oesophagostomum radiatumAdults and fourth-stage larvae
 Bunostomum phlebotomumAdults and fourth-stage larvae
 Nematodirus helvetianusAdults
 N. spathigerAdults
LungwormsDictyocaulus viviparusAdults and fourth-stage larvae
Liver FlukesFasciola hepaticaAdults
GrubsHypoderma bovis
H. lineatum
Parasitic stages
Sucking LiceLinognathus vituli
Haematopinus eurysternus
Solenopotes capillatus
 
Mange mites

Psoroptes ovis

(syn. P. communis var. bovis)
Sarcoptes scabiei
var. bovis

 

IVOMEC® PLUS Injection has been proved to effectively control infections and to protect cattle from re-infection with Dictyocaulus viviparus and Ostertagia ostertagi for 21 days after treatment; Oesophagostomum radiatum, Haemonchus placei, Trichostrongylus axei, Cooperia punctata, and Cooperia oncophora for 14 days after treatment.

 

III. DOSAGE

A.DOSAGE FORMIVOMEC® PLUS Injection is a sterile solution containing 10 mg ivermectin and 2 mg clorsulon/mL.
B.ROUTE OF ADMINISTRATIONIVOMEC® PLUS Injection should be administered by subcutaneous injection.
C.RECOMMENDED DOSAGES:200 mcg ivermectin and 2 mg/kg body weight (1 mL/110 lb body weight)

 

IV. EFFECTIVENESS

IVOMEC® Injection for Cattle is identical to IVOMEC® PLUS Injection for Cattle except that it does not contain clorsulon. Because clorsulon is not active against nematodes, the two products would be expected to show similar efficacy. Data demonstrating the effectiveness of IVOMEC® PLUS Injection for Cattle for previously registered therapeutic indications are discussed in the parent NADA 140-833 FOI Summary (approval date September 17, 1990). In this original approval, demonstration of equivalence of IVOMEC® Injection for Cattle and IVOMEC® PLUS Injection for Cattle was considered sufficient for the therapeutic claims. For the persistence claims for IVOMEC® PLUS Injection for Cattle, only one study in a representative parasite species was necessary to include all species that were granted a persistence claim under NADA 128-409. The effectiveness of IVOMEC® Injection for Cattle for the persistent efficacy indications listed above was demonstrated by data discussed in the supplemental NADA 128-409 FOI Summary (approval date February 24, 1997).

Data from the following dose confirmation trial demonstrate that IVOMEC® PLUS Injection for Cattle given at the recommended dosage is similar to IVOMEC® Injection for Cattle with respect to effective control of infections and protection from re-infection with Dictyocaulus viviparus for 28 days after treatment.

Note: Nematode percentage efficacies were calculated if there were six adequately infected controls using the following formula: 

[Arithmetic mean number of nematodes in control cattle) - (Arithmetic mean number of nematodes in ivermectin/clorsulon-treated cattle)] ¸ (Arithmetic mean number of nematodes in control cattle) ´ 100 = Percent Effectiveness A. Dose Confirmation: Trial ASR 15065

  1. Investigator: Bruce N. Kunkle, D.V.M., M.S. Ph.D., Merial Limited, Fulton, Missouri
  2. General design:
    1. Purpose: To evaluate the persistent efficacy of IVOMEC® PLUS against artificially induced infections of Dictyocaulus viviparus.
    2. Animals: Thirty (30) Holstein calves (10 per group). Animals were approximately 4 to 5 months old and weighed 157 to 234 kg at the start of the study. Animals were free of patent infections at the time of treatment, having been raised under parasite-free conditions and treated with fenbendazole on Days –41 and -18.
    3. Controls: Control animals received the vehicle for IVOMECÒ Injection for Cattle (the same vehicle used for IVOMEC® PLUS) at 1 mL/50 kg body weight. One group received a medication which is not pertinent to this document.
    4. Infection: Infective larvae were given to each animal daily, starting on the day after treatment, according to the following schedule: Dictyocaulus viviparus (50 larvae per day for 28 days).
    5. Test article administration: The approved formulation of injectable solution containing 10 mg ivermectin per mL was administered by subcutaneous injection. One mL/50 kg body weight (200 mcg ivermectin/kg body weight) was given once.
    6. Pertinent variables measured: Worm counts were determined at necropsy which was 49 to 50 days after treatment, 21 to 22 days after the last Dictyocaulus viviparus larvae were administered.
  3. ResultsDictyocaulus viviparus was present in adequate numbers for a determination of efficacy.

    Table 4.1. Arithmetic mean worm counts of Dictyocaulus viviparus recovered for each group and percent efficacy

    Parasite

    Arithmetic Mean
    Control

    Arithmetic Mean
    IVOMEC PLUS

    Percent
    efficacy

    Dictyocaulus viviparus

    20.3

    0.0

    100

  4. Adverse reactions: One animal died 22 days after treatment. The apparent cause of death was an esophageal impaction, which was not believed to be related to the experimental treatment.
  5. Conclusion: This study is adequate to establish a level of persistent efficacy for Dictyocaulus viviparus for 28 days.

 

V. ANIMAL SAFETY

As discussed in the parent NADA 128-409 FOI Summary (approval date February 7, 1984).

 

VI. HUMAN SAFETY

As discussed in the parent NADA 140-833 FOI Summary (approval date September 17, 1990) and in the supplement to NADA 128-409 FOI Summary (approval date September 12, 1994).

 

VII. AGENCY CONCLUSION

The data submitted in support of this supplemental NADA satisfy the requirements of section 512 of the Federal Food, Drug, and Cosmetic Act and implementing regulations at Part 514 of Title 21, Code of Federal Regulations (21 CFR 514) to demonstrate that IVOMEC® PLUS Injection for Cattle, when used under the proposed conditions of use, is safe and effective to control infections and to protect cattle from re-infection with Dictyocaulus viviparus for 28 after treatment.

For cattle, the tolerance of residues are specified in 21 CFR 556.344 and 21 CFR 556.163. A tolerance for the marker residue (22, 23-dihydro-avermectin B1a) of ivermectin is
100 ppb in the liver (target tissue) and 10 ppb in the muscle, and the tolerance for clorsulon (marker residue) in kidney (target tissue) is 1.0 ppm. The withdrawal time is 49 days following one subcutaneous injection of IVOMEC® PLUS Injection for Cattle as specified in 21 CFR 522.1193.

The agency has concluded that this product shall retain over-the-counter marketing status because adequate directions for use have been written for the layman and the conditions for use prescribed on the label are likely to be followed in practice.

In accordance with 21 CFR 514.106(b)(2), this is a Category II change which did not require a reevaluation of the safety or effectiveness data in the parent application.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant impact on human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Under section 512(c)(2)(F)(iii) of the FFDCA, this approval for food producing animals qualifies for three (3) years of marketing exclusivity beginning on the date of approval because the supplemental application contains substantial evidence of the effectiveness of the drug involved, any studies of animal safety, or, in the case of food producing animals, human food safety studies (other than bioequivalence or residue studies) required for the approval of the application and conducted or sponsored by the applicant. The three years of marketing exclusivity applies only to the new claim for which the supplemental application is approved.

IVOMEC® PLUS Injection for Cattle is under U.S. patent number 4,853,372, which expires on August 1, 2006.

 

VIII. APPROVED PRODUCT LABELING (attached)

  • Facsimile base label and package outsert for the 1000 mL container,
  • package insert for the 50, 200, 500, and 1000 mL containers, and
  • bottle label and box carton for the 50 mL container.

Copies of applicable labels may be obtained by writing to the:

Freedom of Information Office
Center for Veterinary Medicine, FDA
7500 Standish Place
Rockville, MD 20855